Low-Dose or High-Dose Conditioning Followed by Peripheral... | NCT00322101

NCT00322101

ID	Type	Description	Link
NCI-2010-00737	Registry Identifier	CTRP (Clinical Trial Reporting Program)
P01CA078902	U.S. NIH Grant/Contract		View source
K23HL084054	U.S. NIH Grant/Contract		View source
P01CA018029	U.S. NIH Grant/Contract		View source
P01HL036444	U.S. NIH Grant/Contract		View source

Status Module

Name	Class
National Cancer Institute (NCI)	NIH
National Heart, Lung, and Blood Institute (NHLBI)	NIH

Description Module

Conditions Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Arm I (Nonmyeloablative regimen)	Experimental	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.	Radiation: total-body irradiation Drug: mycophenolate mofetil Drug: cyclosporine Drug: fludarabine phosphate Procedure: peripheral blood stem cell transplantation Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Other: laboratory biomarker analysis Genetic: cytogenetic analysis Other: flow cytometry Genetic: fluorescence in situ hybridization Other: pharmacological study Genetic: polymorphism analysis
Arm II (Myeloablative regimen)	Experimental	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.	Procedure: allogeneic hematopoietic stem cell transplantation Drug: cyclophosphamide Drug: busulfan Drug: fludarabine phosphate Procedure: peripheral blood stem cell transplantation

Name	Type	Description	Arm Group Labels	Other Names
total-body irradiation	Radiation	Radiation	Arm I (Nonmyeloablative regimen)

Measure	Description	Time Frame
Overall Survival		At 2 years

Measure	Description	Time Frame
Progression-free Survival	IWG criteria was used to determine disease progression	After stem cell infusion to date of last follow up.
Non-relapse Mortality		At 100 days

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Myelodysplastic syndrome (MDS) or transformed acute myelogenous leukemia (transformed from MDS)
De novo acute myelogenous leukemia (AML) beyond first remission
Intermediate or high risk de novo AML in first complete response (at FHCRC unrelated donor recipients only)
Chemotherapy required prior to HCT for all patients:
A) Interval between start of a cycle of cytoreductive chemotherapy and infusion of donor stem cells must be at least 30 days; chemotherapy received for disease maintenance will be allowed during this time period
B) All patients must have < 5% myeloblasts based on marrow morphology performed within 21 days prior to start of conditioning regimen and at least 3-4 weeks after the start of pre-transplant cytoreductive chemotherapy
C) All patients must have no circulating peripheral blood myeloblasts present based on morphologic analysis
Age 65 years or under for patients with related donors; age 60 years or under for patients with unrelated donors
HCT-Specific Comorbidity Index Score (HCT-CI) < 3
Related donor (age > 12 years, nonsyngeneic) or unrelated donor, HLA phenotypically or genotypically identical at the allele level at A,B,C,DRQ1, and CBQ1
DONOR: Related or unrelated donors who are genotypically or phenotypically matched by high resolution HLA typing (HLA-A, B, C, DRB1, and DQB1); class 1 single allele mismatch allowed
DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0201, and this type of mismatch is not allowed
DONOR: A positive anti-donor cytotoxic crossmatch or flow cytometric assay is an absolute donor exclusion at FHCRC/SCCA
DONOR: Age >= 12 years
DONOR: Donors must consent to PBSC mobilization with G-CSF and leukaphereses; bone marrow as a source of stem cells will not be allowed
DONOR: Donor must have adequate veins for leukaphereses or agree to placement of central venous catheter (femoral, subclavian)

Exclusion Criteria:

HIV seropositivity
Fungal infections with radiographic progression after appropriate therapy for greater than one month
Organ dysfunction
Symptomatic coronary artery disease or ejection fraction < 35%
DLCO < 65%, FEV1 < 65% or receiving supplementary continuous oxygen
Liver function abnormalities: Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, histology, and the degree of portal hypertension; patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded
Karnofsky Performance Score < 70
Lansky-Play Performance Score < 70 for pediatric patients
Life expectancy severely limited (< 2 years) by disease other than MDS/AML
Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
Patients with active non-hematological malignancies except:
A) Patients with follicular or low grade lymphoma will be eligible as long as they have not and do not require active treatment for control of their disease
B) Patients with localized non-melanoma skin malignancies
Patients with poorly controlled hypertension who are unable to have blood pressure stabilized below 150/90 mm Hg on standard medication
Females who are pregnant or breastfeeding
Patients with systemic, uncontrolled infections
Active CNS disease as identified by positive CSF cytospin
DONOR: Identical twin
DONOR: Age < 12 years
DONOR: Pregnancy
DONOR: HIV seropositivity
DONOR: Inability to achieve adequate venous access
DONOR: Known adverse reaction to G-CSF

Name	Affiliation	Role
Bart Scott	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
HealthOne Presbyterian St. Lukes Medical Center		Denver	Colorado		United States
Emory University

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
BG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
BG002	Total	Total of all reporting groups

Units	Counts
Participants	BG00014 BG00111 BG00225

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Overall Survival

2 patients in the nonmyeloablative arm did not receive transplant due to relapse and withdrawal of consent

Posted

Number

participants

At 2 years

ID	Title	Description
OG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
OG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Units	Counts
Participants	OG00012 OG00111

Title

Denominators

Categories

Title	Measurements
	OG0006 OG0016

Secondary

Progression-free Survival

IWG criteria was used to determine disease progression

2 patients in the nonmyeloablative arm did not receive a transplant due to relapse and withdrawal of consent

Posted

Number

participants

After stem cell infusion to date of last follow up.

ID	Title	Description
OG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
OG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Secondary

Non-relapse Mortality

2 patients in the nonmyeloablative arm did not receive transplant due to relapse and withdrawal of consent

Posted

Number

participants

At 100 days

ID	Title	Description
OG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
OG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Secondary

Donor Cell Engraftment

Chimerism analysis was performed in patients who recieved nonmyeloablative tranplsnat. In this group the definition of engraftment was a CD3 count greater than 50%. In the myeloablative group, engraftment was defined as an absolute neutrophil count greater than 50%.

2 patients who were randomized to receive nonmyeloablative conditioning did not undergo transplant due to relapse and withdrawal of consent

Posted

Number

participants

After stem cell infusion to day 28

ID	Title	Description
OG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
OG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Secondary

Incidence of Disease Progression/Relapse

Disease progression/relapse was defined by IWG criteria

Posted

Number

participants

After stem cell infusion to date of last follow up.

ID	Title	Description
OG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
OG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Secondary

Incidence and Severity of Acute and Chronic Graft-vs-host Disease

Posted

Number

participants

After transplantation

ID	Title	Description
OG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.
OG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Arm I (Nonmyeloablative Regimen)	CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.			3	12	12	12
EG001	Arm II (Myeloablative Regimen)	CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.			4	11	11	11

Ancestor Terms

ID	Term
D011878	Radiotherapy
D013812	Therapeutics
D008919	Investigative Techniques
D010752	Phosphoramide Mustards
D009588	Nitrogen Mustard Compounds
D009150	Mustard Compounds
D006846	Hydrocarbons, Halogenated
D006838	Hydrocarbons
D009930	Organic Chemicals
D063088	Phosphoramides
D009943	Organophosphorus Compounds
D002208	Caproates
D000144	Acids, Acyclic
D002264	Carboxylic Acids
D005227	Fatty Acids
D008055	Lipids
D002072	Butylene Glycols
D006018	Glycols
D000438	Alcohols
D008698	Mesylates
D000476	Alkanesulfonates
D017738	Alkanesulfonic Acids
D000473	Alkanes
D006839	Hydrocarbons, Acyclic
D013451	Sulfonic Acids
D013456	Sulfur Acids
D013457	Sulfur Compounds
D003524	Cyclosporins
D010456	Peptides, Cyclic
D047028	Macrocyclic Compounds
D011083	Polycyclic Compounds
D010455	Peptides
D000602	Amino Acids, Peptides, and Proteins
D018380	Hematopoietic Stem Cell Transplantation
D033581	Stem Cell Transplantation
D017690	Cell Transplantation
D064987	Cell- and Tissue-Based Therapy
D001691	Biological Therapy
D014180	Transplantation
D013514	Surgical Procedures, Operative
D003584	Cytological Techniques
D019411	Clinical Laboratory Techniques
D019937	Diagnostic Techniques and Procedures
D003933	Diagnosis
D005821	Genetic Techniques
D002469	Cell Separation
D003592	Cytophotometry
D005470	Fluorometry
D008163	Luminescent Measurements
D010783	Photometry
D002623	Chemistry Techniques, Analytical
D017403	In Situ Hybridization
D013194	Staining and Labeling
D016591	Histocytological Preparation Techniques
D006652	Histological Techniques
D009693	Nucleic Acid Hybridization
D016172	DNA Fingerprinting
D016133	Polymerase Chain Reaction
D021141	Nucleic Acid Amplification Techniques
D018942	Macrolides
D007783	Lactones
D000630	Aminopterin
D011622	Pterins
D011621	Pteridines
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring
D006571	Heterocyclic Compounds

Term	Organ System	Statistical Information
severe diarrhea due to gut GVHD	Gastrointestinal disorders	EG0002 events2 affected12 at risk EG0012 events2 affected11 at risk
tachycardia and hypotenstion	Cardiac disorders	EG0001 events1 affected12 at risk EG0010 events0 affected11 at risk
Thrombotic Microangiopathy	Blood and lymphatic system disorders	EG0000 events0 affected12 at risk EG0011 events1 affected11 at risk
Mucositis	Gastrointestinal disorders	EG0000 events0 affected12 at risk EG0011 events1 affected11 at risk

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Mucositis	Gastrointestinal disorders				EG0000 events0 affected12 at risk EG0016 events6 affected11 at risk
Infection	Infections and infestations				EG00012 events12 affected12 at risk EG0015 events5 affected11 at risk

ID	Term
D015470	Leukemia, Myeloid, Acute
C563551	Myeloproliferative Syndrome, Transient
D000013	Congenital Abnormalities
C535323	Chromosome 5q Deletion Syndrome
D009196	Myeloproliferative Disorders

ID	Term
D007951	Leukemia, Myeloid
D007938	Leukemia
D009370	Neoplasms by Histologic Type
D009369	Neoplasms
D006402	Hematologic Diseases
D006425	Hemic and Lymphatic Diseases
D009358	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
D001855	Bone Marrow Diseases

ID	Term
D014916	Whole-Body Irradiation
D003520	Cyclophosphamide
D009173	Mycophenolic Acid
D002066	Busulfan
D016572	Cyclosporine
C042382	fludarabine phosphate
D036102	Peripheral Blood Stem Cell Transplantation
D020732	Cytogenetic Analysis
D005434	Flow Cytometry
D017404	In Situ Hybridization, Fluorescence
D054458	Amplified Fragment Length Polymorphism Analysis
D016559	Tacrolimus
D008727	Methotrexate
C015342	merphos